Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” The once-daily oral small molecule APOL1 inhibitor, ...
There was an error while loading. Please reload this page.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results